Summary of Purpose
To evaluate the effect of antiphospholipid antibodies (aPL) positivity on recurrent stroke or thrombotic events.Read More →
The following dates are available for this trial. Trial information last updated on 16 July 2008.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- National Institute for Neurological Disorders and Stroke, NIH
Study uses patients enrolled in WARSS, a randomized and double-blind secondary stroke and death prevention trial comparing aspirin and warfarin in two treatment arms. Antiphospholipid antibody status at baseline on all WARSS enrolled subjects. aPL status will also be documented yearly and at the time of a recurrent thrombo-occlusive event for all aPL(+) patients and one matched aPL(-) patient for each aPL(+) patient to ensure blinding of aPL status at each of the WARSS clinical centers.